SARS virus hyperimmune globulin - Cangene

Drug Profile

SARS virus hyperimmune globulin - Cangene

Alternative Names: Coronavirus virus hyperimmune globulin - Cangene

Latest Information Update: 28 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cangene Corporation
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronavirus infections

Most Recent Events

  • 21 Feb 2014 Emergent BioSolutions acquires Cangene Corporation
  • 19 Jun 2007 This programme is still active, although the future need of a SARS immune globulin is unknown
  • 20 Oct 2003 Cangene has entered into a research and development agreement with the NIAID to develop a hyperimmune for the potential treatment of SARS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top